Clinical applications of mifepristone

References

• Baird D T. Overview of abortion techniques. Modern methods of inducing abortion, D T Baird, D A Grimes, P FA Van Look. Blackwell Science, Oxford 1995; 25–38
   Google Scholar
• Fiala C, Gemzell-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception 2006; 74: 66–86
   PubMed Web of Science ®Google Scholar
• World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol 2000; 107: 524–530
   Google Scholar
• El-Refaey H, Rajasekar D, Abdalia M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995; 332: 983–987
   PubMed Web of Science ®Google Scholar
• Ashok P W, Penney G C, Flett G MM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998; 13: 2962–2965
   PubMed Web of Science ®Google Scholar
• World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstet Gynaecol Scand 2001; 80: 447–451
   Google Scholar
• Kapp N, Borgatta L, Ellis S C, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. Contraception 2006; 73: 525–527
   PubMed Web of Science ®Google Scholar
• World Health Organization. Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. Br J Obstet Gynaecol 2001; 108: 738–742
   Google Scholar
• Heikinheimo O, Kekkonen R. Dose–response relationship of RU 486. Ann Med 1993; 25: 71–76
   PubMed Web of Science ®Google Scholar
• Schaff E A, Fielding S L, Westhoff C, Ellertson C, Eisinger S H, Stadalius L S, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. J Am Med Assoc 2000; 284: 1948–1953
   PubMed Web of Science ®Google Scholar
• Murthy A S, Crenin M D, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception 2005; 71: 333–336
   PubMed Web of Science ®Google Scholar
• Fox M C, Crenin M D, Harwood B. Mifepristone and vaginal misoprostol on the same day for abortion from 50–63 days' gestation. Contraception 2002; 66: 225–229
   PubMed Web of Science ®Google Scholar
• Ashok P W, Flett G M, Templeton A. Termination of pregnancy at 9–13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet 1998; 352: 542–543
   PubMed Web of Science ®Google Scholar
• Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second trimester abortion. Obstet Gynecol 1997; 90: 896–900
   PubMedGoogle Scholar
• El-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester. A radnomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). Hum Reprod 1993; 8: 1744–1746
   PubMedGoogle Scholar
• Ho P C, Chan Y F, Lau W. Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomized comparative trial. Contraception 1996; 53: 281–283
   PubMed Web of Science ®Google Scholar
• Wong K S, Ngai S W, Chan K S, Tang C H, Ho P C. Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double-blind placebo-controlled trial. Contraception 1996; 54: 23–25
   PubMedGoogle Scholar
• Wong K S, Ngai C SW, Wong A Y, Tang L CH, Ho P C. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998; 58: 207–210
   PubMed Web of Science ®Google Scholar
• Rodger M W, Baird D T. Pretreatment with mifepristone reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Osbtet Gynaecol 1990; 97: 41–45
   PubMedGoogle Scholar
• Ho P C, Ma H K. Termination of second trimester pregnancy with sulprostone and mifepristone: a randomized double-blind placebo controlled trial. Contraception 1993; 47: 123–129
   PubMed Web of Science ®Google Scholar
• Webster D, Penney G, Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynaecol 1996; 103: 706–709
   PubMedGoogle Scholar
• Heikinheimo O, Suhonen S, Haukkamaa M. One- and 2-day mifepristone–misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 2003; 8: 236–239
   Google Scholar
• Johnson N. Intracervical tents: usage and mode of action. Obstet Gynecol Surv 1989; 44: 410–420
   PubMedGoogle Scholar
• Ngai S W, Tang O S, Lao T, Ho P C, Ma H K. Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod 1995; 10: 1220–1222
   PubMed Web of Science ®Google Scholar
• Ngai S W, Au Yeung K C, Lao T, Ho P C. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomized study. Br J Obstet Gynaecol 1996; 103: 1120–1123
   PubMedGoogle Scholar
• El-Refaey H, Calder L, Wheatley D N, Templeton A. Cervical priming with prostaglandin E1 analgues, misoprostol and gemeprost. Lancet 1994; 343: 1207–1209
   PubMed Web of Science ®Google Scholar
• Henry A, Haukkamaa M. Comparison of vaginal misoprostol and gemeprost as pre-treatment in first trimester pregnancy interruption. Br J Obstet Gynaecol 1999; 106: 540–543
   Google Scholar
• Clark K, Ji H, Feltovich H, Janowski J, Carroll C, Chien E. Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events. Am J Obstet Gynecol 2006; 194: 1391–1398
   PubMed Web of Science ®Google Scholar
• Ngai S W, Au Yeung K C, Lao T, Ho P C. Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Contraception 1995; 51: 347–350
   PubMed Web of Science ®Google Scholar
• Ngai S W, Chan Y M, Tang O S, Ho P C. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod 1999; 14: 2139–2142
   PubMed Web of Science ®Google Scholar
• Lelaidier C, Baton-Saint-Mleux C, Fernandez H, Bourget P, Frydman R. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod 1993; 8: 492–495
   PubMed Web of Science ®Google Scholar
• Wagaarachchi P T, Ashok P W, Narvekar N, Smith N C, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod 2001; 16: 1849–1853
   PubMed Web of Science ®Google Scholar
• Gronlund A, Gronlund L, Clevin L, Andersen B, Palmgren N, Lidegaard O. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002; 81: 1060–1065
   PubMed Web of Science ®Google Scholar
• Webb A MC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU 486) in oral postcoital contraception. Br Med J 1992; 305: 927–931
   PubMed Web of Science ®Google Scholar
• Glasier A, Thong K J, Dewar M, Mackie M, Baird D T. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992; 327: 1041–1044
   PubMed Web of Science ®Google Scholar
• Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 1999; 353: 697–702
   PubMed Web of Science ®Google Scholar
• World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428–433
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Piaggio G, Ding J. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803–1810
   PubMed Web of Science ®Google Scholar
• Brown A, Cheng L, Lin S, Baird D T. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double blind randomized controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002; 87: 63–70
   PubMed Web of Science ®Google Scholar
• Baird D T, Brown A, Critchley H OD, Williams A R, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18: 61–68
   PubMed Web of Science ®Google Scholar
• Baird D T, Brown A, Cheng L, Lin S, Narvekar N, Critchley H OD, Williams A R. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids 2003; 68: 1099–1105
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Swahn M L, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993; 8: 870–873
   PubMed Web of Science ®Google Scholar
• Perrault D, Eisenhauer E A, Pritchard K I, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1996; 14: 2709–2712
   PubMed Web of Science ®Google Scholar
• Grunberg S M, Weiss M H, Spitz I M, Ahmadi J, Sadun A, Russell C A, Lucci L, Stevenson L L. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74: 861–866
   PubMed Web of Science ®Google Scholar
• Kettel L M, Murphy A A, Morales A J, Yen S S. Preliminary report on the treatment of endometriosis with low dose mifepristone (RU 486). Am J Obstet Gynecol 1998; 178: 1151–1156
   PubMed Web of Science ®Google Scholar
• Murphy A A, Morales A J, Kettel L M, Yen S S. Regression of uterine leiomyomata to the antiprogesterone RU 486: dose–response effect. Fertil Steril 1995; 64: 187–190
   PubMed Web of Science ®Google Scholar
• Rocereto T F, Saul H M, Aikins J A, Paulson J. Phase II study of mifepristone (RU 486) in refractory ovarian cancer. Gynecol Oncol 2000; 77: 429–432
   PubMed Web of Science ®Google Scholar
• DeBattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab 2006; 17: 117–121
   PubMed Web of Science ®Google Scholar